Terpenoids are a very prominent class of natural compounds produced in diverse genera of plants, fungi, algae and sponges. They gained significant pharmaceutical value since prehistoric times, due to their broad spectrum of medical applications. The fragrant leaves of Eucalyptus trees are a rich source of terpenoids. Therefore this review starts by summarizing the main terpenoid compounds present in Eucalyptus globulus, E. citriodora, E. radiata and E. resinifera and describing their biosynthetic pathways. Of the enormous number of pharmaceutically important terpenoids, this paper also reviews some well established and recently discovered examples and discusses their medical applications. In this context, the synthetic processes for (-)-menthol, (-)-cis-carveol, (+)-artemisinine, (+)-merrilactone A and (-)-sclareol are presented. The tricyclic sesquiterpene (-)-englerin A isolated from the stem bark of the Phyllanthus engleri plant (Euphorbiaceae) is highly active against certain renal cancer cell lines. In addition, recent studies showed that englerin A is also a potent and selective activator of TRPC4 and TRPC5 calcium channels. These important findings were the motivation for several renowned research labs to achieve a total synthesis of (-)-englerin A. Two prominent examples -Christmann and Metz -are compared and discussed in detail.
The search for pharmaceutically useful natural compounds from terrestrial and marine sources has been an ongoing endeavor throughout history and continues to be highly important today. Nowadays it became standard routine to screen newly discovered and isolated natural products for their pharmaceutical properties, resulting in the characterization of a multitude of novel valuable medicines in a short time.
Two very prominent classes of natural products with pharmaceutical activity are the terpenes and terpenoids. Their broad spectrum of medical applications has elicited human interest since prehistoric times by the Aboriginals in Australia who used plant material containing terpenes and terpenoids as medicine. The term "terpene" originates from the tree resin terpentine (German: Terpentin; lat. Balsamum Terebinthinae) which contains hydrocarbons with a repetitious isoprene unit as monomer [1] . In the literature the terms terpene and terpenoid are commonly used interchangeable without clearly distinguishing between them.
Terpenoids are produced in diverse genera of plants, algae and sponges. A rich source of terpenoids is the genus Eucalyptus, whose fragrant leaves quickly caught the attention of early European settlers in Australia. The initial chemical analysis of the ingredients of eucalyptus oil led e.g. to the development of still very popular eucalyptus-based cough medicines, which have beneficial effects on the bronchia. Subsequently a few of the nearly 900 Eucalyptus species and their subspecies known today [2] were thoroughly investigated with regards to their terpene content [3] . Particularly the species Eucalyptus globulus [4] and Eucalyptus citriodora [4c, 5] have been found to contain high quantities of essential oil in their leaves. The chemical composition of the essential oils and amount of terpenes differ between species and vary depending on the habitat of the tree and the harvest time of the leaves.
Main terpenoid compounds in Eucalyptus globulus, E. citriodora, E. radiata and E. resinifera
The chemical composition of the leaf essential oil of Eucalyptus globulus was found by the application of gas chromatography and mass spectrometry to be 40-85% of 1,8-cineol (eucalyptol) (1) , <1-12% of -pinene (2), <1-18% of limonene (3), <1-9% of p-cymene (4), <1-8% of -terpinene (5), <3% of -terpineol (6) , <3% of terpinene-4-ol (7) , <2% of -myrcene (8) , <2% of -phellandrene (9) and <2% of -pinene (10) ( Figure 1) [4]. The essential oil of Eucalyptus citriodora exhibits a completely different relative percentage composition comprising 57-85% of (+)-citronellal (11) and up to 7% of (-)-isopulegol (12) as well as minor amounts of 1,8-cineol, (1) and -pinene (2) [4c, 5] ( Figure  2 ).
Other prominent Eucalyptus species i. e. Eucalyptus radiata and Eucalyptus resinifera contain 69% [6] and 52% [7] of 1,8-cineol (1) as the main component, respectively. 
Biosynthesis of Terpenoids
Eucalyptus oil predominantly consists of simple terpenes which are isolated from different parts of the plant, mainly from the foliage, by steam distillation and subsequent fractional distillation or chromatography.
In 1860 the French chemist P. E. M. Berthelot first observed that some terpenes are built up periodically [8] . In 1887 O. Wallach (Nobel prize for chemistry 1910) hypothesized that terpenoids are polymerization products of pentene C 5 H 8 (isoprene) [9] . L. Ruzicka (Nobel prize for chemistry in 1939) formulated the isoprene rule and the biogenesis of terpenic compounds in 1953. The isoprene rule states that the carbon skeleton of the terpenes is composed of isoprene units linked in regular (head to tail) and irregular arrangement [10] . The isoprenoid compounds derive from acyclic precursors, e. g. geraniol (C-10), farnesol (C-15) , geraniolgeraniol (C-20) , and squalene (C-30) ( Figure 3) [10]. J. Bonner suggested in the first half of the last century that "active isoprene" might be a precursor for the biosynthesis of natural rubber [11] . During his research on B-vitamins F. A. Lipman (Nobel prize for medicine in 1953) [12] discovered coenzyme A (CoA) in 1945, thereby further advancing research on plant metabolism [13] . F. Lynen and K. Bloch (Nobel prize for physiology or medicine in 1964) [14] largely elucidated the biosynthetic pathway of terpenes and fatty acids through the discovery of the elementary building block acetyl-CoA (named by Lynen in German aktivierte Essigsäure) in 1951 [14a, 15] . Initially, Lynen investigated the transformation of acetic acid to citric acid, a process formulated by Krebs in 1937 [16a] and known as the citric acid cycle or Krebs cycle (Nobel prize for Physiology or Medicine in 1953) [16b] . After a half century of his discovery its advances in research was also reviewed [16c].
The biosynthesis of terpenoids starts with three acetyl-CoA units which form the central intermediate mevalonic acid, the precursor for isopentyl pyrophosphate (IPP) and its double bond isomer dimethylallyl pyrophosphate (DMAPP). These building blocks can be considered as "active isoprenes". DMAPP condenses with IPP to the geranyl pyrophosphate (GPP), which after reaction with another DMAPP forms farnesyl pyrophosphate (FPP). In this fashion the biosynthetic pathway continues stepwise to the tetraterpenes (carotinoids) and eventually to polyisoprene (Scheme 1) [17] . All terpenoids are formed by key enzymes, the so called terpene synthases which transform the basic units into a multitude of cyclic and acyclic forms. The chief causes of terpenoid diversity are the large number of different terpene synthases and the fact that some terpene synthases produce multiple products [18a] . The biosynthetic pathway which takes place within the cytosol, the cytoplasm of the cell, does not only occur in higher plants but in other living systems as well [18b].
The mevalonate-based biosynthesis of some prominent cyclic monoterpenoids is described in Scheme 2a and 2b. Scheme 2a shows the formation of reactive ionic intermediate (4R)-α-terpinylcation (R)-(20), whilst in Scheme 2b the further reaction of cation (R)-20 to 1,8-cineol (1) , (+)-limonene (21), (+)-α-terpineol (22), (+)-α-pinene (23) and (-)-β-pinene (25) The following reaction catalyzed by 2-C-methyl-D-erythritol cyclodiphosphate synthase (e5) is remarkable, as it leads to the only known cyclic diphosphate in nature, 2-C-methyl-D-erythritol-2,4cyclodiphosphate (33). Subsequently, 1-hydroxy-methyl butenyl diphosphate synthase (e6) catalyzes the formation of 1-hydroxy-2methyl-2-(E)-butenyl-4-phosphate (34), which is the common precursor for IPP (17a) and DMAPP (17b) formed by IPP/DMAPPsynthase (e7) in a ratio of 5:1 (Scheme 3) [19e, 24] . The further reaction of 17a and 17b leads via geranylpyrophosphate (18) to terpenoids as described in Scheme 2b.
Pharmaceutically relevant Terpenoids
Since terpenoids are naturally formed in a stereospecific manner, they can be obtained in enantiopure form by extraction from natural sources. Because the pure enantiomeric form is needed for the production of highly active medical compounds they are of high value for the pharmaceutical industry. Generally, the first step towards potential application of newly isolated terpenoids from plants and marine sources as medicine is to evaluate their Jaeger & Cuny cytotoxicity. A number of research laboratories around the world are specialized to perform these tests. For this purpose they developed cell-based cytotoxicity assays using e.g. connective tissue cell lines from mouse, human somatic cells or cell lines from rat, cow or pig in 3D-cell culture systems. Depending on the initial results further screening tests are performed stepwise, before successful candidate compounds can go into clinical trials, which finally decide whether an active compound is developed further for human pharmaceutical application.
Following the isolation and characterization of pharmacologically active terpenoids, the possibilities for a synthetic access and largescale production are evaluated, as in many cases the isolation from natural sources is too expensive and the demand is often much higher than nature's supply. In a number of cases a semisynthesis from easily accessible natural products was a feasible alternative for fast, efficient and large-scale production of natural product pharmaceuticals. This type of approach has been discussed by Arndt et al. [59] . Moreover, the development of new lead structures based on natural products is equally important [60] . For example, antibiotics lose their activity due to the known fact of resistance formation in microbes [61a] . Therefore, the continuous search for new natural product antibacterials, e.g. ß-lactams, penicilines and cephalosporins, as well as the development of new derivatives from those existing compounds is necessary. The significance [61b], emerging trends [61c] and re-emerging role [61d] of natural products in antibiotic discovery has been reviewed previously in detail. Polymer therapeutics, another new concept to develop drugs with improved stability and pharmacokinetic properties, has been extensively described by Haag and Kratz [62] .
As mentioned above, numerous terpenoids are naturally synthesized in plants via the mevalonate pathway starting from the basic unit isoprene. Of the enormous number of phytogenic terpenoids which gained pharmaceutical importance, some well established and recently discovered examples are listed in Table 1 , together with their origin and application.
Surprisingly, terpenoids are also produced in fungi, such as (-)fusidic acid (67), which is produced in Fusidium coccineum and other Fusidium species. In 2014 fusidic acid was firstly isolated from a plant, the procumbent annual herb Corchorus aestuans (Tiliaceae). Significant natural terpenoids have also been found in diverse marine organisms, for example brown algae and sponges. Some notable terpenoids synthesized in all these organisms are listed in Table 2 . 
Synthesis of significant terpenoids
From the terpenoid natural products shown in Tables 1 and 2, here we describe the synthetic processes of some well known as well as newly discovered examples having importance as pharmaceuticals for the chemical industry. These are (-)-menthol (36), (-)-ciscarveol (37), (+)-artemisinin (41), (-)-englerin A (45), (-)merrilactone (47), and (-)-sclareol (48). In addition two total syntheses of (-)-englerin A, which is a very potent agent against certain cancer cells, are compared and discussed.
(-)-Menthol
The most recent technical process for (-)-menthol (36) developed by BASF starts from geraniol (68) or neral (69) The synthetic route shown here is only one of the numerous possible syntheses that have been developed for this very important natural product. It can also be obtained starting from β-pinene (Takasago-Process), thymol (Haarmann-Reimer-or Symrise-Process) as well as other starting materials [27a] .
(-)-cis-Carveol
The monocyclic terpene (-)-cis-carveol (37) is easily obtained by a chemo-and diastereoselective reduction of commercially easily accessible R-(-)-carvone (70) . The carbonyl transformation to the alcohol can be performed with lithium aluminium hydride (Scheme 5), Luche-reagent (sodium borohydride-cerium chloride) or with DIBAH (diisobutyl aluminium hydride) [64] . (-)-cis-carveol (37) has shown positive results in prevention of breast cancer, although it remains unclear whether the enantiopure natural product or the racemate is active [28] .
(+)-Artemisinin (71) which could be performed in engineered yeast [66] . The following diasteroselective reduction to dihydroartemisinic acid (72) was successful either by hydrogenation on a chiral rhodium [67] or ruthenium catalyst [68] as well as with hydrazine hydrate derived diimide [69] .
The Seeberger-process consists of a continuous photochemical transformation. After a light-induced oxidation with singlet oxygen (73), an acid catalyzed cleavage (Hock) (74), and oxidation with triplet oxygen delivers (+)-artemisinin (44) One year later, 2013, the Keasling group together with the company Amyris published a high-level semi-synthetic production of the potent antimalaria agent artemisinin on a laboratory scale (no mp and optical rotation were given). The chemical synthesis described was conceived to be suitable for scale-up (130-300 tons per annum) [67] . Approximately 50-60 tons of (+)-artemisinin (44) are produced by this process per year, covering about 50% of the worldwide demand of the chemical industry. This production volume can be achieved by large-scale biotechnological production of (+)-artemisinic acid (71) from recombinant bakers yeast (Saccharomyces cerevisae), on which the process is based. After diastereoselective hydrogenation of the vinylic C-C-double bond under 22 bar pressure and in the presence of the chiral ruthenium-phanephos 78 as catalyst, dihydroartemisinic acid (72) is obtained in nearly quantitative yield and excellent diastereoselectivity (95:5). Subsequent conversion to the anhydride 76 followed by a one-pot reaction cascadephotooxidation with singlet oxygen from air ( 77) and a concatenation of steps, as Hock cleavage and cyclization -yields the product (+)-artemisinin (44). Tetraphenylporphyrine (TPP) is used as an efficient sensitizer for the photooxidation. With 55% the total yield for this process is remarkably high, resulting in an impressive total production volume of 60 tons in 2014. After crystallization the semisynthetic (+)-artemisinin (44) is a white crystalline powder with mp 159°C and [α] D 20 = + 74-78 (c = 1.00, EtOH) [68] .
A comparison of the two industrial processes -the initial chemistry path by Amyris and the new generation process by Sanofi -has been described [68] .
In 2013 a one-pot synthesis of (+)-artemisinin (44) on a gram-scale was described by Wu et al. In this laboratory procedure the singlet oxygen was generated from hydrogen peroxide and catalytic amounts of sodium molybdate (dark singlet oxygen). The intermediate 71 was not isolated, but further reacted with oxygen (balloon) in the presence of trifluoro acetic acid. After work up and chromatography (+)-artemisinin (44) 
(-)-Merrilactone A
The neuroprotective compound (-)-merrilactone A (47) [38] , but was later found to be an error. The correct value of (-)-merrilactone A (47) For the above mentioned reasons (-)-merrilactone A has attracted considerable attention from many renowned synthesis laboratories [73] . 
(-)-Sclareol
The bicyclic diterpene alcohol (-)-sclareol (48) posesses anticancer activity [39a-e] and is a fragrance ingredient used in decorative cosmetics, fine fragrances, shampoos and other toiletries [39f]. The biosynthetic pathway in its native host (Salvia sclarea) was reconstructed in 2012 by Schalk et al. with the help of genetically modified Echerichia coli. Scalerol titers of ~1.5 g per liter are achieved by this biochemical procedure [74] .
The pathway for sclareol biosynthesis in Salvia sclarea was published in parallel by Caniard et al. This group characterized it using genetically modified yeast and identified the same two new diterpene synthases [75] .
Scheme 10: Biosynthetic pathway of (-)-Sclareol in Salvia sclarea.
The biosynthetic pathway of (-)-sclareol (48) starts with the protonation and addition of water to geranyl-geranyl diphosphate (79) and leads to labda-13-en-8-ol-diphosphate (80) . During this reaction, catalyzed by synthase e1, the decalin framework is formed. By means of the sclareol synthase e2 and the addition of a second molecule of water with subsequent elimination of the diphosphate residue results in the natural product 48 with the terminal double bond and the new stereocenter at C-13 (Scheme 10) [74] .
Notable synthetic targets starting from (-)-sclareol (48) are shown in Scheme 11. The sclareol analogue (81) can be prepared in one step. It has been shown to induce selective autophagic cell death in chemo-resistant androgen-independent prostate cancer cells. However, this effect was not observed with the parent compound (-)-sclareol (48) [76] . (-)-Ambrox (82) a constituent of ambergris and very important product in perfumery is produced on large scale by partial synthesis from (-)-sclareol [77] . Furthermore, (-)-15oxopuupehenoic acid (83) [78] , (+)-coronarin E (84) [79] , (+)subersic acid (85) [80] as well as the complex sesterterpenoids (-)sesterstatin 4 and (+)-scalarolide [56d] can be prepared from (-)sclareol (48), emphasizing its importance as starting material to produce a variety of natural products and analogues thereof. 
(-)-Englerin A
The tricyclic sesquiterpene (-)-englerin A (45) isolated from the stem bark of the East African plant Phyllanthus engleri (Euphorbiaceae) by Beutler et al. in 2008 [36a] exhibits potent selective cytotoxicity against renal cancer cells. It showed 1000fold selectivity for six of eight renal cancer cell lines in the NCI-60 panel of human cancer cell lines used by the Developmental Therapeutics Program of the U.S. National Cancer Institute to screen chemical compounds and natural products [36a] . (-)-Englerin A selectively induced necrosis [36b] as well as multiple mechanisms of apoptosis and autophagy [36c] in human renal cancer cells. Therefore, (-)-englerin A is a promising potential therapeutic lead for the treatment of renal cancers. Recent studies from Waldmann et al. showed that englerin A is also a potent and selective activator of TRPC4 and TRPC5 calcium channels [81] .
In 2009 Christmann et al. developed a total synthesis to elucidate the absolute configuration of natural (-)-englerin A. The readily available monoterpene trans,cis-nepetalactone, the volatile oil of catnip (Nepeta cataria), was chosen as starting material. After 15 synthetic steps (+)-englerin A (ent-45) ([a] D 20 = +51° (c = 0.58,MeOH) was obtained [82] . Shortly after, the same group also synthesized the enantiomer (-)-englerin A with [a] D 20 = -63° (c = 0.13, MeOH). They also revealed that (-)-englerin A (45) is highly cytotoxic (IC 50 = 45 nmol) whereas the (+)-enantiomer is inactive up to 1 μmol. This synthesis is not only applicable to obtain gramscale quantities of the natural product, but it is also flexible enough to allow selective modification of both side chains. Based on these findings new (-)-englerin A derivatives with improved activity profile could be synthesized [83] .
An excellent overview of relevant literature on biological studies and other total syntheses of (-)-englerin A (45) until 2015 is given by Hashimoto et al. [84a] . A Chinese review with English commented reaction schemes is published by Guizhou et al. [84b] .
Total syntheses of (-)-Englerin A by Christmann and Metz, respectively
In view of the interesting approach by Christmann et al. to synthesize the cytotoxic agent (-)-englerin A and considering Metz et al. published a similar strategy in 2013 leading to the synthesis of this promising natural product [85] , both total syntheses will be described in detail. 
Methodological approaches
The methodology of the total syntheses of (-)-englerin A (45) is shown in a retrosynthetic fashion in Scheme 12 for the group of (a) Christmann [83] and (b) Metz [85] .. Similar features of both syntheses are the introduction of the exocyclic ester function, the stereoselective linkage of the oxygen bridge originating from an epoxide at C-6 and C-7 and the formation of the carbocyclic seven membered ring by a ring closure metathesis (RCM).
The different ways to obtain the precursor for the RCM-reaction as well as the introduction of the oxygen at C-9 and C-10 by epoxydation rearrangement or dihydroxylation are caused by the different starting materials: (-)-nepetalactone (90), Christmann and (-)-photocitral (95), Metz. Both can be derived from the terpenoids (+)-citronellal (11) and (-)-isopulegol (12) , respectively.
It is of particular interest to note that both educts are introduced into the target molecule in a most economical way. The cyclopentane ring as well as the exocyclic atoms marked in red (Scheme 12) originate from the educts. All three stereogenic centers of the (-)photocitral (95) are used in the synthesis of Metz, whereas in the Christmann synthesis, which starts from (-)-nepetalactone (90), only two are introduced and the third chiral center at C-5 is inverted. The retrosynthetic resolution of the target molecule (45) to these two educts was without doubt an intellectually challenging accomplishment.
Accessibility of the starting materials
The monoterpene (-)-nepetalactone (90) -the starting material of the Christmann synthesis -is obtained from (+)-citronellal (11) in multi gram quantities after four reaction steps according to the protocol of Schreiber et al. [86] . It should be noted that 11 is an industrial compound and educt for the production of (-)-menthol (36) by the BASF company as described before (Scheme 4).
In the synthesis of is oxidized in the allylic position according to Sharpless et al. [87] ( 96), followed by an intramolecular Diels-Alder reaction of the intermediary formed enamine (97) as shown by the arrows. The obtained bicyclic adduct 98 has now three new stereogenic centers in addition to the one of the starting material (+)-citronellal (11) . In the next step one of them is destroyed under acid hydrolysis, yielding the lactol 99. This compound is easily oxidized by Fetizon's reagent to provide (-)-neptalactone (90) in an overall yield of 22% (Scheme 13a)
The starting material (-)-photocitral (95) which is used by Metz can be synthesized in two different ways from commercial available terpenoids (Scheme 13b).
As described in the original publication on the total synthesis of (-)englerin A [85] , (-)-photocitral (95) is obtained from (-)-isopulegol (12) . After oxidative cleavage with lead tetraacetate the obtained open chain aldehyde 100 is cyclized by dual catalysis with Pd(0) catalyst and pyrrolidine. The initially obtained mixture of photocitral diastereomeres is equilibrated with base, subsequently reduced with lithium aluminium hydride to the alcohol and at this stage purified by column chromatography. Reoxidation with 2iodoxybenzoic acid (IBX) in DMSO yields (-)-photocitral (95) in an overall yield of 47%. The product is pure enough as starting material for the total synthesis of (-)-englerin A (45).
During this route, two of the original three stereogenic centers of (-)-isopulegol (12) are destroyed and subsequently formed again (Scheme 13b).
Method of MacMillan
Parallel to the publication by Metz et al. the group of MacMillan et al. described a one-step approach to gain (+)-photocitral (ent-95) from (-)-citronellal (ent-11). The intramolecular α-alkylation of aldehydes with simple olefins to homo-ene products forms two new stereogenic centers. This reaction affords -with the help of the single electron oxidizing agent iron(III) trisphenantroline trisbis(trifluoromethylsulfonyl)amide and the ligand (R,R)-101 -the desired (+)-photocitral (ent-95) in one step in 65% yield and with the remarkable diastereomeric ratio of 17:1 [88] .
Transferring this reaction to the preparation of the enantiomeric (-)photocitral (95) requires the readily availability of the iron catalyst and the ligand (S,S)-101 (Scheme 13b).
Total syntheses
In Scheme 14 and 15 the individual reaction steps and intermediates of the (-)-englerin A synthesis of Christmann [83] and Metz [85] , respectively, are depicted. Preparative and mechanistic details are described in their respective publications. Therefore only the key reactions and the strategic differences of both routes are discussed Scheme 15: Metz group total synthesis of (-)-Englerin A.
Christmann et al. set up the seven membered ring by a RCM reaction in step 9 (109) under formation of a C-C-double bond between C-6 and C-7 (15 mol%, ruthenium catalyst). Therefore the desired stereochemistry at C-6 and C-7 had to be built up at the end of the synthesis. This was realized by a stereoselective epoxidation (8887) in a diastereoselective ratio of 5.4:1. After the subsequent transannular cyclization the minor isomeric epoxide could easily separated from compound 86 by chromatography. The other two stereocenters (C-9, C-10) are formed early in the synthesis by an epoxylactone rearrangement, followed by a stereoselective Reformatzki reaction (89103). The two stereoisomers were seperable by chromatography (Scheme 14). Metz et al. also form the seven membered ring by a RCM reaction, however, this is achieved in the second step already (112) by formation of a C-C-double bond between C-9 and C-10 (1 mol% same catalyst). The four stereocenters of the cycloheptane ring are generated at a late stage of the synthesis by chemo-and stereoselective epoxidation (115) and subsequent cishydroxylation (92) in a diastereomeric ratio of 2:1. The isomers were separated by chromatography (Scheme 15).
Most notable is the interesting biomimetic transannular epoxidation by simple warming up in chloroform (Christmann 86) or treatment with 2N HCl, respectively (Metz 117).
The overall yields of both syntheses with regard to diastereomeric ratios are specified in a) Scheme 13 for the starting materials and b) in Scheme 14 and 15 for the total syntheses. Based on this calculation the Christmann synthesis has an overall yield of 3% with regard to (+)-citronellal (11) as starting material, whilst the Metz synthesis has an overall yield of 7% with (-)-isopulegol (12) as educt. Starting from (+)-citronellal (11) would shorten this synthesis and improve the overall yield of the product.
In addition to this considerable preparative results -only the first steps (11  96 and 90  102, Christmann), (12  100, Metz) occur with relative low yield -both syntheses are also suitable for the synthesis of derivatives of (-)-englerin A (45), which may be even more effective than the natural product itself. Many promising candidates towards this goal have already been successfully generated in the Christmann group [83] .
Conclusion remarks
Within the last few years the number of newly identified pharmaceutically active compounds based on natural products is growing rapidly, as indicated by the similarly increasing number of publications on the topic. However, even today there is still an unsatisfied clinical requirement for new therapeutics against numerous diseases. For example, we need better drugs to target the various forms of cancer for which no efficient treatments are available yet. An ongoing challenge in this field is the task of targeting cancer cells with high selectivity while leaving healthy tissue undamaged. Here, natural-product terpenoid compounds, such as (-)-englerin A and its derivatives seem to be very promising candidates.
Furthermore new medical compounds are needed in the field of antibiotics, as bacterial pathogens can acquire resistances against the antibiotics we currently use. Furthermore, new life-threatening diseases, for which no cures are available, are emerging at alarming rates. The risk of contagious diseases spreading quickly and causing epidemics is severely increased in today's globalized and highly mobile society. Therefore we need to have a continuous supply of effective antibiotics. In this context great hopes and expectations lie on the almost inexhaustible source of natural products still waiting to be discovered and examined for potential medical uses. Terpenoids, in particular, represent a major and important class of natural products, and those characterized so far have numerous valuable pharmaceutical qualities and medical uses. Therefore it is not surprising that terpenoids are synthesized and studied in many laboratories, and those already characterized are processed on a large scale by the chemical and pharmaceutical industries.
